What the three trials found
The Lancet trial, led by Klausen and colleagues in Copenhagen, is the largest and longest of the three.
It gave 108 adults living with both alcohol use disorder and obesity either Wegovy at 2.4 mg weekly or a placebo for 26 weeks, with everyone also receiving cognitive behavioural therapy.1
Heavy drinking days fell by 41.1 percentage points on semaglutide and by 26.4 percentage points on placebo, a difference of 13.7 percentage points.1
A heavy drinking day in this trial meant more than 6 UK units in a day for a woman, about two large glasses of wine, or 7.5 for a man, a little over three pints of ordinary-strength lager.1 The other two trials put the threshold slightly higher.2,3
Measured as total alcohol, everyone was consuming around 64 units a week when the trial started.1
The semaglutide group reduced their intake by roughly 45 units a week, and the placebo group, with the same therapy, roughly 30. The difference between the two, around 15 units a week, is the reduction semaglutide itself added, slightly more than the entire UK weekly guideline.1
People are poor at reporting their own drinking, so the researchers also measured three blood markers that change with alcohol intake.
The most useful is phosphatidylethanol. It’s a compound that forms in the blood only when alcohol is there, so nothing else can raise it, and it reflects alcohol intake over the previous four or so weeks. It decreased more on semaglutide than on placebo.1
Gamma-glutamyl transferase, or GGT, is a liver enzyme that increases when the liver has been processing a lot of alcohol over the last few months. It decreased by 24.2 U/L more in the semaglutide group than in the placebo group.1
The third is mean cell volume, the average size of a red blood cell, which increases over months of heavy drinking. It decreased by 1.7 fL more in the semaglutide group.1
GGT and red cell size can both change for reasons that have nothing to do with alcohol, such as other liver problems, an underactive thyroid, or low vitamin B12.
Still, all three markers decreased alongside people’s own reported intake, which is strong evidence that the intervention led to a reduction in alcohol consumption.
The JAMA Psychiatry trial, run by Hendershot and colleagues in 2025, recruited 48 adults who weren’t seeking treatment for their drinking. It was a phase 2 study, meaning a small trial designed to test whether a treatment works at all before larger ones run.2
This trial used a much lower dose than people take for weight loss. Participants were on 0.5 mg a week when their drinking was measured, a fifth of Wegovy’s 2.4 mg dose.2
Rather than asking people what they drank, the researchers watched them drink. Participants were given access to alcohol in a supervised session before they started the medication, and again eight weeks later.2
Even at the 0.5 mg dose, they drank less the second time and their peak breath alcohol reading was lower. They also had fewer drinks on the days they drank, and fewer heavy drinking days, while the number of days they drank at all didn’t change.2
The American Journal of Psychiatry trial, led by Schacht and colleagues in July 2026, gave 50 adults with moderate to severe alcohol use disorder semaglutide as a daily tablet for eight weeks.3
The main question this trial set out to answer was whether semaglutide reduces alcohol cravings (our desire to drink alcohol in the first place).
Researchers put participants in front of their usual drink and measured how much they wanted it, and, interestingly, semaglutide made no difference.3
The researchers also recorded how much everyone was drinking. Participants started the trial on around six U.S. standard drinks a day, with about five heavy drinking days a week.3
A U.S. standard drink is a fixed measure of 14 g of alcohol, where a UK unit is 8 g. So six of them a day is close to 11 UK units.
On semaglutide, that reduced by about one drink on each drinking day, roughly two UK units, or a pint of beer. Their heavy drinking days fell too.3
They also used cannabis on fewer days.3 That suggests semaglutide isn’t doing something specific to alcohol, but making rewarding things in general feel less rewarding.
The people in all three trials were living with alcohol use disorder, so the results may not describe what happens for people drinking at more ordinary levels.
Many members on the Second Nature programme tell us they’re drinking less simply because they don’t want to as much.
The laboratory finding is specifically about wanting a drink that’s already in front of you. When trial participants reported their cravings in ordinary daily life, those did fall, which fits what members describe.2,3
Member reports aren’t evidence in the way a trial is, though, and no trial has tested these medications in people without a drinking problem, so we don’t yet know how far these results extend.
| Trial |
Form and dose |
People and length |
Main finding |
| Klausen, Lancet 2026 |
Injection, 2.4 mg weekly |
108 adults, 26 weeks |
Heavy drinking days fell 13.7 percentage points more than placebo; blood markers for alcohol intake also reduced |
| Hendershot, JAMA Psychiatry 2025 |
Injection, 0.5 mg weekly at assessment |
48 adults, 9 weeks |
Less alcohol drunk in a lab session, lower peak breath alcohol, less heavy drinking |
| Schacht, Am J Psychiatry 2026 |
Tablet, 3 mg then 7 mg daily |
50 adults, 8 weeks |
Fewer heavy drinking days, but no change in laboratory craving |
What about people who don’t have an alcohol disorder?
No trial has tested Wegovy’s effect on drinking in people who drink moderately. All three studies we’ve reviewed in this article recruited heavy drinkers, because that’s who a treatment for alcohol problems would be for.
The evidence for the general population comes from studies of participants taking these medications for weight loss or type 2 diabetes.
The most direct research available is a survey of 153 people living with obesity taking semaglutide or tirzepatide, the drug in Mounjaro.4 Compared with before they started, and with similar people not on the medication, they drank less overall, had fewer drinks in each session, and were less likely to binge drink.
A second study followed 83,825 people living with obesity through their medical records for a year. Those prescribed semaglutide were 50% to 56% less likely to be diagnosed with an alcohol problem, or to fall back into an old one, than those on other weight-loss medications.5
Neither study randomly assigned anyone, and the first relied on people reporting their own drinking, so they show a pattern rather than prove the medication caused it.
Still, when we consider the above evidence with the new trials on individuals living with alcohol use disorder, there does seem to be a positive effect of Wegovy and other GLP-1 medications on reducing alcohol intake.
Does Wegovy reduce alcohol cravings?
Wegovy seems to reduce how much people think about alcohol day to day, without changing how much they want a drink that’s already in front of them.
Both findings come from the tablet trial. When researchers put participants’ usual drink in front of them, semaglutide made no difference at all: people wanted that drink just as much as they ever had.3
The same participants also rated their cravings in everyday life, away from the laboratory. There, semaglutide did make a difference: people reported wanting to drink less through the week.3
The JAMA Psychiatry trial asked people about their cravings every week and found that people on semaglutide reported weaker cravings than people on placebo.2
So semaglutide doesn’t seem to reduce how much we want a drink that’s in front of us. What it seems to reduce is the desire to have one in the first place.
People on these medications describe a similar experience with food on GLP-1 medications.
Food noise, the intrusive persistent thoughts about eating, quietens, while they’ll still crave their favourite foods if they’re presented with them. Some have started calling the drinking version of this experience ‘alcohol noise’.
The urge to drink is often developed through learned associations in the brain. For example, we might have a drink when we get home from work to unwind after a hard day.
Over time, our brain learns that the cue of returning home after work is associated with the reward of enjoying an alcoholic drink.
Wegovy seems to make each further drink less rewarding, but the routine, cues, and feelings that prompt the first one are still there. That may be why people drank on just as many days, but simply drank less when they did.
Drinking fell in all three trials, whichever way craving was measured, so the reduction doesn’t seem to depend on craving alone.
How long after your injection can you drink?
You don’t need to wait a set amount of time between your injection and a drink.
Semaglutide has a half-life of about a week, meaning it takes that long for half a dose to leave the body. It’s in your system continuously, so there’s no point in the week where it has cleared and nothing to time your drinking around.6
For the same reason, skipping a dose so you can drink at an event like a wedding won’t help. One missed injection doesn’t clear the drug in time, and it interrupts your treatment.
At Second Nature, we recommend minimising alcohol consumption to improve overall health, whether you’re on a GLP-1 medication or not.
The more useful question isn’t how many hours to leave after injecting, but how much you’re drinking across the week and whether it’s impacting your health.
The UK guideline is no more than 14 units a week, spread over three days or more rather than saved up.
Still, you might experience more pronounced side effects like nausea in the 24-48 hours after each injection. In this scenario, it would make sense to avoid drinking alcohol during this time as it could make the side effects worse.
If you feel your current level of drinking is affecting your health, we’d recommend reflecting on the habits around it, what prompts a drink and when, rather than on the timing of your injections.
Does the Wegovy pill also reduce alcohol intake?
Probably, though it hasn’t been tested at the pill’s licensed dose for weight loss. The Wegovy pill was approved in the UK in June 2026 and contains the same drug as the injection.
The American Journal of Psychiatry trial used oral semaglutide and found fewer heavy drinking days, but at 3 mg then 7 mg daily, the dose range used in Rybelsus for type 2 diabetes. The Wegovy pill goes up to 25 mg, more than three times that.3
Whether the higher 25 mg dose will support a bigger reduction in alcohol intake hasn’t been tested.
Still, alcohol consumption was reduced on the 0.5 mg injection, the 7 mg tablet, and at the 2.4 mg injection, suggesting there’s a consistent link between Wegovy and reduced drinking at a wide range of doses.
Do you get drunk faster on Wegovy?
The most common thing people on GLP-1 medications report about alcohol is getting drunk faster, or drunk on less than they used to manage. But interestingly, the one study that has measured it found the opposite.
Quddos and colleagues gave 20 people living with obesity, half of them on a GLP-1 medication, a set dose of alcohol and tracked their breath alcohol readings.7
The rise in breath alcohol was slower in the GLP-1 group, and their readings were lower in the first 10 to 20 minutes. They also reported feeling less intoxicated, not more.7
Still, this was a pilot study of 20 people; the authors describe the findings as preliminary, and not everyone in it was taking semaglutide.
Semaglutide slows the rate at which our stomach empties, so alcohol reaches the bloodstream more slowly and the peak is lower, which is exactly what the breath readings showed.
That study measured the medication’s effect on its own. In everyday life, being on Wegovy also changes how much we eat, and an emptier stomach has the opposite effect: with less food to slow it down, alcohol is absorbed into the bloodstream faster, and the same drink can feel stronger than it did before.
Losing a lot of weight may also change how we respond to alcohol, because alcohol spreads through the water in our body and less body fat and lean mass will mean we hold onto less water, too. However, this isn’t likely to have a significant effect.
Since the medication itself slows how quickly alcohol is absorbed, reports of patients getting drunk faster most likely come from individuals potentially eating too little while on the medication, rather than from the effect of the drug itself.
Worse hangovers are also commonly reported, but this isn’t something that’s been investigated, so it’s unclear what the potential link there might be to GLP-1 drugs specifically.
Eating less before drinking and losing fluid through nausea, vomiting, and diarrhoea could both make a hangover worse, but none of this has been tested.
Still, everyone’s response to Wegovy is different, and some people may notice no impact from the medication in how they respond to alcohol.
Drinking safely on Wegovy
Alcohol doesn’t appear anywhere in Wegovy’s Summary of Product Characteristics, the official UK prescribing document, and no formal interaction between the two is listed.6
While no interaction has been established, there are a few plausible ways that Wegovy and alcohol may directly and/or indirectly interact with one another.
The clearest of these is blood sugar, which alcohol and semaglutide lower in different ways.
Alcohol stops the liver releasing its stored glucose (sugar) into the blood, and that effect can last for up to 24 hours after we finish drinking.
Semaglutide lowers blood sugar too, but it only prompts the body to release insulin when sugar is already high, so on its own it rarely causes hypoglycaemia (blood sugar that falls too low).6
The risk rises for people who also take insulin or a sulfonylurea such as gliclazide for type 2 diabetes. Those medications lower blood sugar regardless of its baseline, and because alcohol stops the liver from responding to low blood sugar, drinking makes a hypo more likely.6
A hypo can also be mistaken for being drunk, since slurred speech, unsteadiness, confusion, and sweating occur in both situations.
Alcohol and GLP-1 medications have both been linked to acute pancreatitis, a sudden inflammation of the pancreas.
Pancreatitis has been reported in people taking GLP-1 medications, including severe and fatal cases, and the prescribing document advises stopping the medication if it’s suspected.6 Heavy drinking is separately one of the two most common causes in the UK, alongside gallstones.
No study has measured whether pancreatitis is more likely when heavy drinking and a GLP-1 medication are combined, so this interaction is theoretical, but plausible.
Still, pancreatitis is a rare side effect of GLP-1 medications, listed as ‘uncommon’ in the prescribing document, meaning it affects fewer than 1 in 100 people taking it, so the risk is low.6
Another possible interaction is the impact Wegovy and alcohol have on the stomach.
Alcohol irritates the stomach lining, and Wegovy’s most common side effects are stomach and gut related: nausea affects around 44% of people taking it, diarrhoea around 30%, and vomiting around 25%. Drinking on top of that may make an unsettled stomach worse, though no study has tested the combination.6
Alcohol also makes us pass more urine, and repeated vomiting or diarrhoea loses fluid as well, so together they can lead to dehydration, which in rare cases affects how the kidneys work.6
When to speak to your prescriber
Most people can drink moderately on Wegovy without any problem. We’d recommend contacting your GP or prescriber if you have:
- Severe stomach pain that spreads through to your back, particularly with vomiting, which can be a sign of pancreatitis
- Repeated vomiting or diarrhoea after drinking, or signs of dehydration such as dark urine and dizziness on standing
- Episodes of low blood sugar, if you take insulin or a sulfonylurea
- If you’re concerned that your current alcohol intake is impacting your health
If severe stomach pain comes on suddenly and doesn’t ease, go to A&E. Pancreatitis needs assessing the same day.
Some people avoid mentioning their drinking in case the medication is stopped. In most cases, your prescriber will simply want to know, so they can check your blood sugar and your liver, and tell you what to watch for.
Wegovy isn’t a treatment for alcohol dependence
Semaglutide has no licence for alcohol use disorder from the MHRA, the European Medicines Agency, or the FDA.
Wegovy’s UK licence covers weight management, cardiovascular risk reduction, and liver disease with moderate to advanced scarring.6
Any use of it to reduce drinking is off-label, and no UK prescriber can offer it for that purpose through a weight-loss service.
Licensed treatments do exist, with a far larger evidence base than three small trials. Acamprosate and naltrexone reduce alcohol cravings, disulfiram makes drinking physically unpleasant, and nalmefene is licensed specifically to reduce how much someone drinks.8
Other treatments are also available on the NHS, such as cognitive behavioural therapy, a talking therapy with good evidence for helping people drink less.8
If you’re concerned about your drinking habits, your GP can refer you to a local alcohol service, which gives you access to those medications alongside psychological support.
Everyone in the Lancet trial received cognitive behavioural therapy, and the placebo group’s heavy drinking days still fell by 26.4 percentage points on that therapy alone, compared with 41.1 on the medication and therapy together.1
So most of the reduction in alcohol intake in both groups came from the therapy rather than the drug, which is the opposite of how this research is usually reported.
Frequently asked questions
Can you drink alcohol while taking Wegovy?
Yes. There’s no listed interaction between alcohol and semaglutide in the UK prescribing document, and no requirement to avoid it.6
The considerations are low blood sugar if you also take insulin or a sulfonylurea, pancreatitis risk with heavy drinking, and worsening any nausea you already have.
Should I skip a dose so I can drink at a wedding or other social event?
No. The drug stays in your system for weeks, so skipping one injection won’t clear it in time to make any difference, and it interrupts your treatment for no gain.6
Why does Wegovy make you not want to drink?
Semaglutide activates the GLP-1 receptors in the parts of our brain involved in reward, the same parts that respond to alcohol.
Activating them appears to make alcohol less rewarding, which is the leading explanation for why the amount people drink falls.1
Why are hangovers worse on Wegovy?
No study has measured hangover severity on semaglutide, so there’s no evidence that Wegovy does directly make hangovers worse.
Eating less before drinking and losing fluid through nausea or diarrhoea are the most plausible explanations, but neither has been tested.
What alcohol is best to drink on Wegovy?
No type of alcohol has been shown to be better tolerated than another. Many people find wine less appealing and switch to a spirit with a sugar-free mixer, though that’s preference rather than clinical advice.
Take home message
Three randomised trials published between 2025 and 2026 found that semaglutide reduces drinking in people living with alcohol use disorder, and the largest showed heavy drinking days falling by 13.7 percentage points more than placebo over 26 weeks.1
The number of days people drank didn’t change. The amount on those days did, by around two UK units in the tablet trial, which is roughly a pint of beer.2,3
Wegovy can make alcohol less rewarding, but it doesn’t change the brain’s learned associations that may trigger us to drink in the first place.
If we’re in the habit of drinking when we get home from work every day, we may still continue that habit, but drink less due to the drug’s effects.
All three trials were small, ran for 26 weeks or less, and studied people drinking around 64 units a week rather than people taking Wegovy to lose weight.
Survey and medical-record studies of people taking these medications for weight loss show a similar pattern of reduced alcohol intake.4,5
Semaglutide is in your system all week, so which day you drink on doesn’t matter. Still, we recommend minimising alcohol consumption to improve our overall health, whether we’re on GLP-1 medications or not.
Speak to your prescriber if you get severe stomach pain spreading to your back, repeated vomiting after drinking, or low blood sugar episodes if you take insulin or a sulfonylurea.
Semaglutide isn’t licensed to treat alcohol dependence. If your drinking concerns you, acamprosate, naltrexone, disulfiram, and nalmefene are licensed for that purpose and available through your GP.8
Our guide on whether Mounjaro helps you drink less alcohol covers the equivalent evidence for tirzepatide.
Second Nature’s programme combines medication with personalised support from registered dietitians and nutritionists, built around a balanced plate of vegetables, protein, complex carbohydrates, and healthy fats.
A peer-reviewed study published in JMIR Formative Research found that active subscribers on Second Nature’s semaglutide-supported programme lost an average of 19.1% of their body weight at 12 months, with 77.7% achieving at least 10% weight loss.9
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
